Walgreens, CVS, Meijer’s & Walmart CoQ-10 Class Action Settlement
The Class is defined to mean “all persons in the United States who purchased a Lang CoQ-10 Softgel product manufactured by Lang Pharma Nutrition, Inc. (hereafter, “Lang CoQ-10 Softgel”) and sold under store brand labels by CVS, Wal-Mart, Walgreens and Meijer (“the Retailers”), from July 1, 2013 until July 24,2018.
- Wal-Mart’s Equate Clinical Strength High Absorption CoQ-10 100 mg
- CVS/Pharmacy Ultra CoQ-10 100 mg
- CVS/Health Ultra CoQ-10 100 mg
- CVS/Pharmacy Enhanced Absorption Formula CoQ-10 100 mg
- CVS/Health Enhanced Absorption Formula CoQ-10 100 mg
- Walgreens Well at Walgreens CoQ-10 Enhanced Absorption Formula 100 mg
- Walgreens Well at Walgreens CoQ-10 Enhanced Absorption Formula 200 mg
- Meijer’s Ultra CoQ-10 100 mg (“Meijer Ultra CoQ-10”)
Class Members who file a valid claim form must choose between a partial cash refund of $3.50 pro rata or a product credit valued at $12.50
Proof of Purchase
William Jackson, et al. v. Lang Pharma Nutrition Inc., et al., Case No. 37-2017-00028196-CU-BC-CTL,
Superior Court of California for the County of San Diego
This matter is a continuation of four earlier CoQ-10 cases involving the Retailer defendants (except Meijer). These Prior CoQ-10 Cases involved CoQ-10 products manufactured by Lang Pharma Nutrition, Inc. and sold by the Retailers. The names of the Prior CoQ-10 Cases are: (1) Thamar Santisteban Cortina v. Wal-Mart, Inc. et al., Case No. 13-cv-020540, United States District Court for the Southern District of California; (2) Leo Harris v. CVS Pharmacy, Inc., Case No. 5:13-cv-02329, United States District Court for the Central District of California; (3) Raymond Alvandi v. CVS Pharmacy, Inc., Case No. 2:15-cv-01503, United States District Court for the Central District of California; and (4) Gary Reynolds, et al. v. Walgreens, Inc., Case No. 4:15-cv-00324, United States District Court for the Northern District of California (collectively the “Prior CoQ-10 Cases”).
While litigating the Prior CoQ-10 Cases, the parties engaged in substantial investigations, extensive discovery, motion practice, and intense settlement discussions. The Prior CoQ-10 Cases were dismissed; however, the Cortina court ordered that all discovery conducted in that case could be used by the parties in future CoQ-10 litigation. Subsequent to dismissal, the Prior CoQ-10 Cases were refiled as Jackson et al. v. Lang Pharma Nutrition, Inc. et al.
The proposed settlement class covers the time period of July 1, 2013 to July 24, 2018.